Syncytial virus, the EU authorizes the vaccine for the over 60s
[ad_1]
After the yes of the USA, comes that of Europe. The European Commission has authorised Arexvy, the first vaccine to protect adults 60 years of age and older, against lower respiratory tract disease caused by respiratory syncytial virus (RSV). “The decision marks an important step and has been particularly awaited in light of the increase in RSV infections in the EU last winter – explained the European executive in a statement -. The Arexvy vaccine, now authorized throughout the EU , will help strengthen the immune response to the virus.”
Respiratory infections: rethinking prevention policies for the elderly and frail
by Anna Lisa Bonfranceschi
The rigorous examination of the EMA
The authorization follows a rigorous review conducted as part of EMA’s accelerated evaluation mechanism. And, considering that the prevention of RSV infection in the elderly population is of great interest for public health, the Commission accelerated the authorization of the vaccine.
“This is our first authorized vaccine against RSV and we hope it will prevent some of the problems we encountered last winter – underlined the Health Commissioner, Stella Kyriakides -. The COVID-19 pandemic has clearly shown the need for decisive action to better prepare the EU for emerging health threats. This is a core principle of the strong European Health Union we are building.”
He concluded: “In light of the threat posed by RSV, today we gave priority authorization to the first vaccine to protect older EU citizens from a major health threat. I now encourage Member States to build rapidly on this authorization and define national vaccination strategies so that people most at risk can access them in the coming months before the next autumn season”.
Respiratory syncytial virus, ok subject to pregnancy vaccine
by Roberta Villa
The approval of the vaccine in the USA
The green light in the US for the vaccine against respiratory syncytial virus (RSV) arrived at the beginning of last May. There Food and Drug Administration (Fda) has approved it for people age 60 and older. Arexvy had therefore first received the yes from the United States for the prevention of lower respiratory tract diseases in adults caused by the RSV virus. “Elderly people, especially with underlying medical conditions, such as heart or lung disease or a weakened immune system, are at high risk of serious illness caused by RSV,” he said. Peter Mark, director of the FDA’s Center for Biologicals Evaluation and Research -. The approval of the first RSV vaccine is an important public health achievement to prevent a disease that can be life-threatening.”
Syncytial virus, Moderna presents the vaccine that saves children and the elderly
by Donatella Zorzetto
What is respiratory syncytial virus
RSV is a highly contagious virus that causes lung and respiratory tract infections in people of all ages (it is also known for its impact on newborns). Circulation is seasonal, typically starting during the fall and peaking in the winter. According to the US Centers for Disease Control and Prevention, each year in the United States, RSV leads to an estimated 60,000-120,000 hospitalizations and 6,000-10,000 deaths among adults age 65 and older.
[ad_2]
Source link
